Breast Cancer 360™ Gene Expression Panel
Immune checkpoint blockade has shown tremendous promise in patients with melanoma, however responses remain heterogeneous. Therefore, better biomarkers are needed to identify patients who will benefit from these forms of therapy. Here, we studied a cohort of metastatic melanoma patients treated with CTLA-4 or PD-1 blockade. We performed molecular, immune, and Digital Spatial Profiling in order to identify biomarkers of response and mechanisms of resistance to checkpoint blockade. Furthermore, we investigated the impact of tumor heterogeneity on differential responses to therapy in a subset of patients with synchronous melanoma metastases. These findings provide insights into differential responses to checkpoint blockade.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.